Owlet Inc. (OWLT)
NYSE NYSE Primary 
Owlet Q1 Earnings Call Highlights
Owlet NYSE: OWLT reported first-quarter 2026 revenue above its own guidance while lowering its full-year sales outlook and raising its profitability forecast, as the baby monitoring and pediatric health technology company said it is narrowing its focus to subscriptions, core markets and operational efficiency.
Owlet, Inc. (OWLT) Reports Q1 Loss, Tops Revenue Estimates
Owlet, Inc. (OWLT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.07 per share a year ago.
Earnings Preview: Owlet, Inc. (OWLT) Q1 Earnings Expected to Decline
Owlet (OWLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owlet's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
OWLT posts narrower-than-expected Q4 loss and 29.6% revenue growth on Dream product demand and Owlet360 subscriptions. Yet shares tumble after hours.
Owlet, Inc. (OWLT) Reports Q4 Loss, Tops Revenue Estimates
Owlet, Inc. (OWLT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.07 per share a year ago.
Owlet, Inc. (OWLT) Q4 2025 Earnings Call Transcript
Owlet, Inc. (OWLT) Q4 2025 Earnings Call Transcript
Owlet Stock Before Q4 Earnings: Buy Now or Wait for Results?
OWLT's fourth-quarter results are likely to reflect subscription growth, FDA-backed differentiation and revenue gains, even as tariff pressures weigh on margins.
Owlet Strengthens Healthcare Partnerships: Can Adoption Scale?
OWLT is deepening healthcare partnerships to expand adoption beyond consumers, starting with hospital-prescribed monitoring and broader clinical use cases.
Owlet vs. Masimo: Which Medical Monitoring Stock Is the Better Buy?
Remote and continuous patient monitoring is moving from a niche capability to a core pillar of modern healthcare, driven by aging populations, staffing shortages, and a push toward data-driven care both inside hospitals and at home. Against this backdrop, Owlet, Inc. OWLT and Masimo Corporation MASI represent two very different ways to invest in the same secular trend.
Owlet Broadens Its Product Ecosystem: Can New Devices Drive Growth?
OWLT broadens its product ecosystem with new cameras, bundles and devices, aiming to boost adoption beyond the Dream Sock and drive growth.
Owlet Gains From FDA Clarity: Does Regulation Create an Edge?
OWLT benefits from FDA clarity, boosting credibility, raising barriers and supporting growth via subscriptions.
Owlet Stock Up More Than 82% in the Past 6 Months: Still Worth Buying?
OWLT's 82% surge in the past six months is backed by record Q3 results, FDA leadership and growing subscription momentum.
